Although homogeneity of HER2 amplification and expression is necessary for the success of conventional HER2-targeted therapy, such homogeneity is less frequent for AGC than for breast cancer and is not necessarily required for the success of therapy with trastuzumab deruxtecan. This evidence concerns the gene ERBB2 and breast cancer.